04.01.2021 • NewsPeople

Adrenomed Appoints Wolfgang Baiker as CEO

German biopharmaceutical company Adrenomed has appointed Wolfgang Baiker as Chief Executive Officer (CEO), effective Jan. 1, 2021.

Baiker has over 30 years of experience in the pharmaceutical and biotechnology industry, and until his recent retirement was President and CEO of Boehringer Ingelheim USA. Previously, he held various roles at Boehringer Ingelheim, including Head of Global Development, Head of Global Manufacturing and Global Quality, as well as Head of the Biopharmaceutical Business Unit.

Currently, Baiker is a Venture Partner with Wellington Partners, chairs the Board of Trustees of the Max Planck Institute of Polymer Research and sits on multiple boards of biopharmaceutical start-up companies. He studied medicine at the Universities of Bochum, Berlin, Ulm, Sheffield and Munich and obtained his Ph.D. from the University of Ulm and an MBA from Pace University in New York.

Adrenomed has appointed Wolfgang Baiker as Chief Executive Officer (CEO),...
Adrenomed has appointed Wolfgang Baiker as Chief Executive Officer (CEO), effective Jan. 1, 2021. © Adrenomed

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.